Ignite Creation Date:
2025-12-24 @ 2:38 PM
Ignite Modification Date:
2026-01-07 @ 12:23 AM
Study NCT ID:
NCT02350959
Status:
UNKNOWN
Last Update Posted:
2015-10-07
First Post:
2015-01-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Adverse Plaque Characteristics in CCTA and TVC Imaging
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D058225', 'term': 'Plaque, Amyloid'}], 'ancestors': [{'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069059', 'term': 'Atorvastatin'}], 'ancestors': [{'id': 'D011758', 'term': 'Pyrroles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006538', 'term': 'Heptanoic Acids'}, {'id': 'D005227', 'term': 'Fatty Acids'}, {'id': 'D008055', 'term': 'Lipids'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 100}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2015-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-10', 'completionDateStruct': {'date': '2017-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-10-05', 'studyFirstSubmitDate': '2015-01-16', 'studyFirstSubmitQcDate': '2015-01-29', 'lastUpdatePostDateStruct': {'date': '2015-10-07', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2015-01-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'the change of max LCBI(4mm): Lipid core burden index in 4 mm', 'timeFrame': '1 year', 'description': 'The primary endpoint for this study is the change of max LCBI(4mm) between initial and follow up angiography in non-target vessel'}, {'measure': 'Correlation between vulnerable plaque on CT and max LCBI(4mm)', 'timeFrame': 'maximum duration of 3 months between CT and NIRS', 'description': 'The other primary endpoint of this study is Vessel level correlation of vulnerable plaque on CT and LCBI(4mm)'}], 'secondaryOutcomes': [{'measure': 'the change of presence of maxLCBI(4mm) > 500', 'timeFrame': '1 year', 'description': 'vessel level comparison between initial and follow up angiography in non-target vessel'}, {'measure': 'the change of CT plaque vulnerability', 'timeFrame': '2years', 'description': 'the change of Positive remodeling, Low attenuation plaque, Spotty calcification'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Plaque', 'coronary computed tomography angiography'], 'conditions': ['Plaque']}, 'referencesModule': {'references': [{'pmid': '24037276', 'type': 'BACKGROUND', 'citation': 'de Boer SP, Brugaletta S, Garcia-Garcia HM, Simsek C, Heo JH, Lenzen MJ, Schultz C, Regar E, Zijlstra F, Boersma E, Serruys PW. Determinants of high cardiovascular risk in relation to plaque-composition of a non-culprit coronary segment visualized by near-infrared spectroscopy in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014 Feb;35(5):282-9. doi: 10.1093/eurheartj/eht378. Epub 2013 Sep 12.'}, {'pmid': '23785015', 'type': 'BACKGROUND', 'citation': 'Yonetsu T, Suh W, Abtahian F, Kato K, Vergallo R, Kim SJ, Jia H, McNulty I, Lee H, Jang IK. Comparison of near-infrared spectroscopy and optical coherence tomography for detection of lipid. Catheter Cardiovasc Interv. 2014 Nov 1;84(5):710-7. doi: 10.1002/ccd.25084. Epub 2013 Jul 16.'}, {'pmid': '23871513', 'type': 'BACKGROUND', 'citation': 'Madder RD, Goldstein JA, Madden SP, Puri R, Wolski K, Hendricks M, Sum ST, Kini A, Sharma S, Rizik D, Brilakis ES, Shunk KA, Petersen J, Weisz G, Virmani R, Nicholls SJ, Maehara A, Mintz GS, Stone GW, Muller JE. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2013 Aug;6(8):838-46. doi: 10.1016/j.jcin.2013.04.012. Epub 2013 Jul 17.'}, {'pmid': '24098825', 'type': 'BACKGROUND', 'citation': 'Jaguszewski M, Klingenberg R, Landmesser U. Intracoronary Near-Infrared Spectroscopy (NIRS) Imaging for Detection of Lipid Content of Coronary Plaques: Current Experience and Future Perspectives. Curr Cardiovasc Imaging Rep. 2013;6(5):426-430. doi: 10.1007/s12410-013-9224-2.'}, {'pmid': '22019821', 'type': 'BACKGROUND', 'citation': 'Pu J, Mintz GS, Brilakis ES, Banerjee S, Abdel-Karim AR, Maini B, Biro S, Lee JB, Stone GW, Weisz G, Maehara A. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J. 2012 Feb;33(3):372-83. doi: 10.1093/eurheartj/ehr387. Epub 2011 Oct 20.'}]}, 'descriptionModule': {'briefSummary': 'The present study is intended to assess the vulnerability of plaques seen on CCTA by means of TVC Imaging System and to make comparisons between plaques with adverse plaque characteristics and ones without adverse plaque characteristics in terms of plaque volume and lipid core contents.', 'detailedDescription': 'This study is to be conducted in two phases - Phases 1 and 2. In Phase 1, the vulnerability of plaques seen on CCTA will be assessed with TVC Imaging System, and the plaque volume and lipid core contents of plaques with versus without adverse plaque characteristics will be compared. For the purpose of this study, the study of this phase will be a cross-sectional study in which the shapes of vulnerable plaques seen on CCTA will be compared to their vulnerability visualized by the TVC Imaging System.\n\nIn Phase 2, the patients with multi-vessel (polyvascular) disease of those participating in Phase 1 will be included, and the study of this phase will be a longitudinal study in which serial TVC imaging will be performed for non-target vessels, and any differences in changes of plaque vulnerability when treated with moderate-dose versus high-dose statin will be comparatively analyzed. The purpose of the present study is to determine whether there are any significant differences in changes of plaque volume and stability when treated with high-dose versus moderate-dose statin.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age 20 years of older\n2. Patients with typical chest pain or evidences of myocardial ischemia (e.g., stable, unstable angina, silent ischemia and positive functional study or reversible changes in the electrocardiogram (ECG) consistent with ischemia\n3. Patients with signed informed consent\n4. Confirmed coronary artery disease in computed tomography\n\nExclusion Criteria:\n\n1. The past history of coronary artery disease (e.g., myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), etc.)\n2. Less than 2-year life expectancy due to non-cardiac disease\n3. If the subject cannot voluntarily agree in writing to participate in this study\n4. If the subject is currently participating in any other study with another investigational drug or medical device\n5. Allergic reaction to iodinated contrast media\n6. Significant renal dysfunction (Serum creatinine \\> 1.5 mg/dl) 7 Heart rate ≥ 80 beats per minute even after treatment with a heart rate lowering medication which disable to take CCTA\n\n8\\. Contraindications of either β blockers or nitroglycerin 9. The past history of complex congenital heart disease 10. Pregnant women or women with potential childbearing 11. Body mass index (BMI) exceeding 35 12. Irregular heartbeats which disable to take CCTA 13. Contraindications of statin due to hypersensitivity, past history of serious complication such as myopathy or increased liver enzyme more than 3 times of normal upper limit'}, 'identificationModule': {'nctId': 'NCT02350959', 'acronym': 'CITRUS', 'briefTitle': 'Adverse Plaque Characteristics in CCTA and TVC Imaging', 'organization': {'class': 'OTHER', 'fullName': 'National Health Insurance Service Ilsan Hospital'}, 'officialTitle': 'Evaluation of Adverse Plaque Characteristics in Coronary Computed Tomography Angiography Using Combined Near Infrared Spectroscopy With Intravascular Ultrasound [CITRUS Study]', 'orgStudyIdInfo': {'id': '2014-11-022'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'High dose statin', 'description': 'In high dose statin group, atorvastatin 40mg will be used', 'interventionNames': ['Drug: Atorvastatin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Moderate dose statin', 'description': 'in moderate dose statin group, atorvastatin 10mg will be used', 'interventionNames': ['Drug: Atorvastatin']}], 'interventions': [{'name': 'Atorvastatin', 'type': 'DRUG', 'description': 'in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography', 'armGroupLabels': ['Moderate dose statin']}, {'name': 'Atorvastatin', 'type': 'DRUG', 'description': 'in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography', 'armGroupLabels': ['High dose statin']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Goyang-si', 'state': 'Gyeonggi-do', 'status': 'RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Kyung-Jin Park', 'role': 'CONTACT', 'phone': '82-10-2442-4029'}], 'facility': 'National Health Insurance Service Ilsan Hospital', 'geoPoint': {'lat': 37.65639, 'lon': 126.835}}], 'centralContacts': [{'name': 'Sanghoon Shin, M.D.', 'role': 'CONTACT', 'email': 'nephilla99@gmail.com', 'phone': '82-10-8961-0707'}], 'overallOfficials': [{'name': 'Sanghoon Shin, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'National Health Insurance Service Ilsan Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Health Insurance Service Ilsan Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director, Clinical Research', 'investigatorFullName': 'Sanghoon Shin', 'investigatorAffiliation': 'National Health Insurance Service Ilsan Hospital'}}}}